MyFiziq teams up with NuraLogix to develop total health smart phone technology
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MyFiziq Limited (ASX:MYQ) has signed a memorandum of understanding (MOU) with Canadian based NuraLogix Corporation.
MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimension using only a smartphone privately and accurately.
NuraLogix is a pioneer of Affective Artificial Intelligence (AI) which is the combination of affective computing and artificial intelligence. It has developed the world’s first cloud-based Affective AI Engine, DeepAffexTM, which utilises the company’s proprietary facial imaging technology, Transdermal Optical Imaging (TOITM).
This is used to predict a wide array of human physiological and psychological effects using nothing more than the video camera found on any smartphone.
Using this technology, the company developed the world's first smartphone app, AnuraTM, which can inform you about your general health and wellness in 30 seconds.
NuraLogix’ patented technology utilises a video camera like that found on a smartphone to take a 30-second selfie video of your face, determining a wide range of physiological and health-related parameters.
These include heart rate, heart rate variability, blood pressure, stress, cardiovascular disease risks and much more with TOI using the video camera to extract blood flow information from the face which is then processed by DeepAffexTM advanced machine learning algorithms that form part of the group’s cloud-based Affective AI Engine.
The MyFiziq image dimensioning capabilities will be combined with DeepAffex and Transdermal Optical Imaging to form a never before seen total health screen from a mobile phone.
The combined digital capability of the two companies, that is due to their patent coverage along with the unique offering, is a one of a kind non-invasive solution that can be used regardless of age.
Applications in gaining advanced warning of chronic health conditions
The resulting information captures and data are assisting individuals in understanding their personal exposure to chronic debilitating diseases that form up to 70% of deaths globally each year, including those that are primarily characterised by irregular blood pressure, heart and respiratory levels.
Consequently, users stand to benefit from seeing the early warning signs of cardiovascular disease, type II diabetes risk and stroke.
Commenting on the significance of these developments and the potential to develop proprietary technologies for a broad market, MyFiziq chief executive Vlado Bosanac said, “This is an extremely exciting partnership for the companies.
‘’Bringing our technologies together will not only create a one of a kind solution, furthermore it will be unrivalled.
‘’Our offerings in a standalone environment have a deep patent suite.
‘’When combining the company solutions, we not only form a unique offering, but one that enhances both companies’ ability to be the dominant player in digital health and convenience.
‘’The solutions form an easy to use, comprehensive review of an individual, accurately, privately, and conveniently from their mobile phone.’’
Opportunity to participate in COVID-19 symptoms analysis
Furthermore, users will have the option to engage in an in-app COVID-19 symptoms analysis, which has been developed and tested, by NuraLogix in collaboration with St. Michael’s Hospital, University of Toronto, and Zhongda Hospital in China to produce an AI based model which was trained and tested on the symptom’s profiles of COVID-19 patients.
The model predicts the likelihood of someone having COVID-19 versus seasonal flu or cold.
NuraLogix has been published previously for its work in determining health parameters via a mobile device in world leading publications such as The American Heart Association - Cardiovascular Imaging.
The doctors and clinicians that collaborated with NuraLogix in concluding the COVID-19 study have determined the outcome to be so significant that the results are being presented for publication.
The Anura COVID sample screen is shown below.
Global organisations have been exploring the potential combination of thermal imaging cameras with drone technology to scan crowds as a measure in the fight against current and future pandemics.
NuraLogix has been looking to be less invasive from a personal perspective, allowing individuals the choice to screen themselves at home or work when they feel they may have been exposed and are showing any of the known symptoms.
An integrated solution for global markets
Under the terms of the MOU, the parties have agreed to develop the application in a demonstrated mobile application (Demo App) combining their technologies to be used to evaluate the potential for a full commercial version of the application over the next 90 day period (Term).
At the end of the Term, should both parties consider the response of potential customers to the Demo App to be promising enough for further pursuit, they shall then negotiate a formal commercial agreement to specify terms including, but not limited to, pricing, revenue sharing, intellectual property, development work and marketing.
MyFiziq and NuraLogix intend to integrate the patented solutions to expand the capabilities of their capture suite for a potential global market.
Initially, they will only offer the Demo App to The Serfaty Clinic in Brazil and WeSure/WeFit in Mainland China. Upon a successful outcome, the company will then look to take the offering to a broader global audience.
MyFiziq has undertaken the entirety of the integration to expedite the process, envisaging completion of the build in readiness for handover in the next 60 days.
tagsARTIFICIAL INTELLIGENCE MOU DEEPAFFEXTM CLOUD BASED AFFECTIVE AI ENGINE COVID 19 TRANSDERMAL OPTICAL IMAGING SMARTPHONE
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.